The short version
4 companies list this market β a reasonable cushion if one runs into trouble.
β How this was built
- FDA NDC Directory (openFDA) β labelers active in the last 30 days, repackagers classified from DailyMed SPL establishment roles
- CMS NADAC β latest price vs the price in effect ~12 months earlier
- FDA drug shortages and enforcement reports (openFDA)
- FDA inspection classifications; DrugDashboards fragility score and 90-day shortage model
Each sentence is a template that fires only when its condition holds in the data shown lower on this page: maker counts are distinct FDA labelers listing this molecule and dosage form in the last 30 days minus classified repackagers; the price trend compares the newest NADAC with the last price in effect at least 9 months earlier; shortage and recall sentences restate FDA rows for this drug's presentations (Class I/II, trailing 12 months); the plant sentence needs a MANUFACTURE-role establishment with a drug-quality OAI in 24 months; the verdict restates the fragility band; the risk sentence appears only when the model's probability is at least 1.5Γ the typical market. Nothing here is inferred beyond those rules.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only β verify against primary sources before acting.